Your browser version may not work well with NCBI's Web applications. More information here...

Recent Activity

Items 1 - 20 of 171
of 9Next
1:

Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice.

Petersén A, Stewénius Y, Björkqvist M, Gisselsson D.

BMC Cell Biol. 2005 Sep 13;6:34.

PMID: 16159402 [PubMed - indexed for MEDLINE]

2:

Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients.

Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, Bates GP.

Hum Mol Genet. 2001 Oct 1;10(21):2425-35.

PMID: 11689489 [PubMed - indexed for MEDLINE]

3:

Expression of the Huntington's disease transgene in neural stem cell cultures from R6/2 transgenic mice.

Chu-LaGraff Q, Kang X, Messer A.

Brain Res Bull. 2001 Oct-Nov 1;56(3-4):307-12.

PMID: 11719265 [PubMed - indexed for MEDLINE]

4:

Inclusion formation in Huntington's disease R6/2 mouse muscle cultures.

Orth M, Cooper JM, Bates GP, Schapira AH.

J Neurochem. 2003 Oct;87(1):1-6.

PMID: 12969246 [PubMed - indexed for MEDLINE]

5:

DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.

Crocker SF, Costain WJ, Robertson HA.

Brain Res. 2006 May 9;1088(1):176-86. Epub 2006 Apr 19.

PMID: 16626669 [PubMed - indexed for MEDLINE]

6:

Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.

Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, Wishart TM, Court FA, Morton AJ.

Eur J Neurosci. 2004 Dec;20(11):3092-114.

PMID: 15579164 [PubMed - indexed for MEDLINE]

7:

Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.

Josefsen K, Nielsen MD, Jørgensen KH, Bock T, Nørremølle A, Sørensen SA, Naver B, Hasholt L.

J Neuroendocrinol. 2008 Feb;20(2):165-72. Epub 2007 Nov 22.

PMID: 18034868 [PubMed - indexed for MEDLINE]

8:

Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.

Gil JM, Leist M, Popovic N, Brundin P, Petersén A.

BMC Neurosci. 2004 May 10;5:17.

PMID: 15134587 [PubMed - indexed for MEDLINE]

9:

Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.

MacGibbon GA, Hamilton LC, Crocker SF, Costain WJ, Murphy KM, Robertson HA, Denovan-Wright EM.

J Neurosci Res. 2002 Feb 1;67(3):372-8.

PMID: 11813242 [PubMed - indexed for MEDLINE]

10:

Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene.

Ishiguro H, Yamada K, Sawada H, Nishii K, Ichino N, Sawada M, Kurosawa Y, Matsushita N, Kobayashi K, Goto J, Hashida H, Masuda N, Kanazawa I, Nagatsu T.

J Neurosci Res. 2001 Aug 15;65(4):289-97.

PMID: 11494364 [PubMed - indexed for MEDLINE]

11:

Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.

Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, Blakemore C, Hannan AJ.

Eur J Neurosci. 2004 May;19(10):2799-807.

PMID: 15147313 [PubMed - indexed for MEDLINE]

12:

The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis.

Björkqvist M, Fex M, Renström E, Wierup N, Petersén A, Gil J, Bacos K, Popovic N, Li JY, Sundler F, Brundin P, Mulder H.

Hum Mol Genet. 2005 Mar 1;14(5):565-74. Epub 2005 Jan 13.

PMID: 15649949 [PubMed - indexed for MEDLINE]

13:

Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.

Bailey CD, Johnson GV.

J Neurochem. 2005 Jan;92(1):83-92.

PMID: 15606898 [PubMed - indexed for MEDLINE]

14:

Physical activity fails to rescue hippocampal neurogenesis deficits in the R6/2 mouse model of Huntington's disease.

Kohl Z, Kandasamy M, Winner B, Aigner R, Gross C, Couillard-Despres S, Bogdahn U, Aigner L, Winkler J.

Brain Res. 2007 Jun 25;1155:24-33. Epub 2007 Apr 21.

PMID: 17512917 [PubMed - indexed for MEDLINE]

15:

Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity.

Morton AJ, Leavens W.

Brain Res Bull. 2000 May 1;52(1):51-9.

PMID: 10779703 [PubMed - indexed for MEDLINE]

16:

Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse.

Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH.

Ann Neurol. 2000 Jan;47(1):80-6.

PMID: 10632104 [PubMed - indexed for MEDLINE]

17:

Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.

Wade A, Jacobs P, Morton AJ.

Brain Res. 2008 Jan 10;1188:61-8. Epub 2007 Jul 14.

PMID: 18062944 [PubMed - indexed for MEDLINE]

18:

Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ.

Mol Ther. 2005 Oct;12(4):618-33.

PMID: 16019264 [PubMed - indexed for MEDLINE]

19:

Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.

Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R.

Hum Mol Genet. 2007 Aug 1;16(15):1845-61. Epub 2007 May 21.

PMID: 17519223 [PubMed - indexed for MEDLINE]

20:

Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment.

Phillips W, Morton AJ, Barker RA.

J Neurosci. 2005 Dec 14;25(50):11564-76.

PMID: 16354914 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 171
of 9Next